Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.63 |
| ▸ | MMP14 | P50281 | 7/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377947 | 0.90 | MMP13 (0.63) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6379017 | 0.85 | MMP14 (0.62) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6377577 | 0.85 | MMP2 (0.66) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6381224 | 0.85 | MMP13 (0.65) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6381559 | 0.84 | MMP13 (0.49) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6378906 | 0.83 | MMP13 (0.90) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6377446 | 0.83 | MMP13 (0.55) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6383329 | 0.83 | MMP13 (0.64) | MMP13MMP14HSPB1ALDH1A1 | |
| SCHEMBL6377105 | 0.83 | MMP14 (0.60) | MMP13MMP14MMP2MMP9MMP3 | |
| SCHEMBL6383331 | 0.82 | MMP13 (0.54) | MMP13MMP14MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202974-B1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-6579982-B1 | Treating inflammation, cancer | PFIZER INC. | 2003-06-17 | — | — | US | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1202974-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012611-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-02-22 | — | — | WO | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| EP-1202974-B1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004073712-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A NOS INHIBITOR AND AN NMDA RECEPTOR ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20030232739-A1 | Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6579982-B1 | Treating inflammation, cancer | PFIZER INC. | 2003-06-17 | — | — | US | disclosed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1284141-A2 | Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases | Pfizer Products Inc. (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1202974-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012611-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | MMP13 2072/4885MMP14 3834/4885MMP2 3340/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | MMP13 3171/4885MMP14 4017/4885MMP2 3475/4885 |
| US-20030232739-A1 | Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist | GRIN1, GRIN2B, GRIN2A | MMP13 2295/4885MMP14 1464/4885MMP2 2772/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | MMP13 272/4885MMP14 275/4885MMP2 231/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | MMP13 3171/4885MMP14 4017/4885MMP2 3475/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | MMP13 2072/4885MMP14 3834/4885MMP2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.